Sparta Pharmaceuticals Inc. Announces the Appointment of Dr. Martin Rose

Most recently Rose was vice president, drug development of Quintiles Worldwide Strategic Consulting. Prior to that, he was with Alpha 1 Biomedicals Inc. where he was senior vice president, clinical and regulatory affairs. Rose was also senior director, government affairs for Genentech Inc. Before that position, he was group leader for the Division of Cardio-Renal Drug Products in the Food and Drug Administration.

Along with his professional experience, Rose has been associated with many trade and professional societies including: the American Society for Clinical Pharmacology and Therapeutics (for which he chaired the section on Clinical Pharmaceutical Development and Regulatory Affairs), the PMA User Fee Task Force, the Institute of Medicine Study on the Use of Advisory Committees by the FDA, the BIO Drug Regulatory Committee (he held the position of chairman for three years) and several FDLI Annual Meeting Planning Committees.

Rose obtained his undergraduate degree, as well as his MD, from the University of California School of Medicine, San Francisco. He earned the degree of Juris Doctor from the University of California School of Law at Berkeley.

Sparta is a development-stage pharmaceutical company engaged in the business of acquiring rights to, and developing for commercialization, technologies and drugs for the treatment of a number of life threatening diseases including cancer, cardiovascular disorders and inflammation.

Edited by Larissa Comis Tis